

EUROPEAN SOCIETY OF ONCOLOGY PHARMACY

Membershipservic e c/o DGOP e.V., Veritaskai 6, 21079 Hamburg, Germany
E-Mail: membershipservic e@esop.li, Fax: +49 (40) 466 500 100
EU-Transparencyregister : <https://ec.europa.eu/transparencyregister/public>



[ESOP c/o DGOP e.V. , Veritaskai 6, 21079 Hamburg](#)

EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR EMPLOYMENT,
SOCIAL AFFAIRS AND INCLUSION
Employment Health and Safety

Charlotte GREVFORS ERNOULT

1049 Bruxelles/Brussel
Belgium

Hamburg, April , 7th 2021

Dear Mrs. GREVFORS ERNOULT

I hope that this letter reaches you and that you are still responsible for this area.

After we visited you a few years ago in Luxembourg and were able to describe the dangerous situation to you and your colleagues, we had the impression that we were able to give you new knowledge about the malicious machinations of some companies.

We have been following the procedures of these companies for decades and can also follow the way they work and their results on another continent.

It is about trying to turn the just struggle for occupational safety into a business model that would withdraw necessary funds from the health care system.

We have pointed out that employees in all companies, including health companies, have a right to appropriate and protection-worthy handling. Nonetheless, experience shows that protection is not achieved through devices, but through safe work processes and work environments.

In the 80s of the last century, employees in many places, including Europe, began to describe the processes of action and to take appropriate precautions. This included taking over the patient-specific cytostatics preparation from the wards in central production areas, mostly in hospital pharmacies.

President: **Klaus Meier** (Germany); Co-President: **Alain Astier** (France); Vice-Presidents **Ewelina Korczowska** (Poland),
Mirjam Crul (The Netherlands), **Ahmet Sami Bosnak** (Turkey), **Christophe Bardin** (France); Secretary:
Roman Gonec (Czech Republic); Treasurer: **Camille Groos** (Luxembourg)

Registre de Commerce et des Sociétés Luxembourg: F8987



Even then there were the defendant companies who criticized this process through the use of plastic additives. Scientific research has shown everyone better. After the manufacturing pharmacies pointed out various additional issues of contamination and the corresponding investigations were carried out, which included the shipping process from the pharmaceutical industry as well as the handling of ready-to-use infusion solutions on the wards, these companies reappeared to turn to offer their plastic as a way out. As you know, they were so bold to hire MEPs for their campaigns.

As a result, after the EP no longer wanted to accept bogus arguments, you were asked to investigate this matter. We have informed you from the beginning that you have resorted to a consortium for the field study whose advisor was precisely the laboratory that had also carried out commissioned work for the incriminated companies in the past.

The implementation of the subsequent online seminars and the refusal to question participating experts about possible conflicts of interest and to disclose them did not contribute to building trust.

I ask you today what happened to the report, the results of which should be available to you?

When will the participating experts and professional associations become informed of the results, so that they can be checked for factual accuracy with the discussions they have experienced?

We expect you to provide information on this as soon as possible and we would like to point out once again our suggestion to carry out a reasonable investigation of the contamination issues.

Hoping for an answer soon

Yours sincerely

Klaus Meier (President)